1. Home
  2. GBTG vs ACAD Comparison

GBTG vs ACAD Comparison

Compare GBTG & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Business Travel Group Inc.

GBTG

Global Business Travel Group Inc.

N/A

Current Price

$9.48

Market Cap

4.9B

Sector

Technology

ML Signal

N/A

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$29.11

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GBTG
ACAD
Founded
2014
1993
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.3B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
GBTG
ACAD
Price
$9.48
$29.11
Analyst Decision
Buy
Buy
Analyst Count
6
22
Target Price
$8.92
$30.55
AVG Volume (30 Days)
1.2M
1.7M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
173.33
69.12
EPS
0.13
0.20
Revenue
$2,718,000,000.00
$726,437,000.00
Revenue This Year
$21.78
$18.80
Revenue Next Year
$4.29
$11.70
P/E Ratio
$72.77
$148.65
Revenue Growth
12.17
40.45
52 Week Low
$4.96
$19.69
52 Week High
$9.54
$30.96

Technical Indicators

Market Signals
Indicator
GBTG
ACAD
Relative Strength Index (RSI) 64.08 57.27
Support Level $9.33 $25.00
Resistance Level $9.51 $30.96
Average True Range (ATR) 0.02 0.87
MACD -0.00 -0.12
Stochastic Oscillator 43.75 47.55

Price Performance

Historical Comparison
GBTG
ACAD

About GBTG Global Business Travel Group Inc.

Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: